News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
Phase 3 pivotal program in hemodialysis patients expected to commence in Q4 2017
View HTML
Toggle Summary Cara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain Conference
STAMFORD, Conn. , Oct. 04, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics to Participate in September Medical Meetings
Data from Phase 2 chronic osteoarthritis pain study of Oral CR845 to be presented in poster session at PAINWeek STAMFORD, Conn. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed
View HTML
Toggle Summary Cara Therapeutics Reports Second Quarter 2017 Financial Results
Conference call today at 4:30 p.m. ET
View HTML
Toggle Summary Cara Therapeutics to Webcast Presentation at the Canaccord Genuity 37th Annual Growth Conference
STAMFORD, Conn. , Aug. 03, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that
View HTML
Toggle Summary Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer
STAMFORD, Conn. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics to Announce Second Quarter 2017 Financial Results on August 3, 2017
STAMFORD, Conn. , July 27, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that
View HTML
Toggle Summary Cara Therapeutics Announces Summary Data From Phase 1 Trial of Oral CR845 in Hemodialysis Patients with Chronic Kidney Disease
Tablet strengths exhibiting appropriate plasma levels identified for potential use in general CKD-associated pruritus patients
View HTML
Toggle Summary Cara Therapeutics Announces Top-line Results From Phase 2b Trial of Oral CR845 in Chronic Pain Patients With Osteoarthritis of the Hip or Knee
- Statistically significant 39 percent reduction in mean joint pain score in hip patients at eight weeks with 5.0 mg dose - - 35 percent reduction in mean joint pain score for all patients at eight weeks with 5.0 mg dose - - All tablet strengths well tolerated over eight-week treatment period - -
View HTML
Toggle Summary Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients
Phase 3 safety extension trial underway
View HTML